HIV特异性细胞毒性T淋巴细胞逃逸：代价几何？
HIV CTL escape: at what cost?
作者信息
Smith Stephen M
机构信息
Saint Michael's Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA.
出版信息
Retrovirology. 2004 May 12;1:8. doi: 10.1186/1742-4690-1-8.
Abstract
Recent data have established the HIV-1 and SIV escape CTL through epitope mutation. However, three novel studies prove that such escape comes at a "cost" to overall viral fitness. Understanding how HIV-1/SIV escape CTL and the impact of the escape mutations has tremendous importance in developing CTL based vaccines. Further, a CTL based HIV-1 vaccine is likely to have long-term protective effect against disease only if the escape virus is significantly weakened compared with wild type.
摘要
近期数据表明，HIV-1和SIV可通过表位突变逃避细胞毒性T淋巴细胞（CTL）。然而，三项新研究证明，这种逃逸是以整体病毒适应性为“代价”的。了解HIV-1/SIV如何逃避CTL以及逃逸突变的影响，对于开发基于CTL的疫苗极为重要。此外，只有当逃逸病毒与野生型相比显著减弱时，基于CTL的HIV-1疫苗才可能对疾病产生长期保护作用。
相似文献
1
HIV CTL escape: at what cost?
Retrovirology. 2004 May 12;1:8. doi: 10.1186/1742-4690-1-8.
2
Reversion of CTL escape-variant immunodeficiency viruses in vivo.
Nat Med. 2004 Mar;10(3):275-81. doi: 10.1038/nm998. Epub 2004 Feb 15.
3
Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
Trends Microbiol. 2005 Jun;13(6):243-6. doi: 10.1016/j.tim.2005.03.011.
4
Rates of HIV immune escape and reversion: implications for vaccination.
Trends Microbiol. 2008 Dec;16(12):561-6. doi: 10.1016/j.tim.2008.09.001. Epub 2008 Oct 27.
5
CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Trends Immunol. 2004 Mar;25(3):138-42. doi: 10.1016/j.it.2004.01.004.
6
Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
J Virol. 2006 Feb;80(4):1949-58. doi: 10.1128/JVI.80.4.1949-1958.2006.
7
Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic-T-lymphocyte escape mutation.
J Virol. 2005 Sep;79(17):11529-32. doi: 10.1128/JVI.79.17.11529-11532.2005.
8
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
J Exp Med. 2004 Jun 21;199(12):1709-18. doi: 10.1084/jem.20040432.
9
HIV and SIV CTL escape: implications for vaccine design.
Nat Rev Immunol. 2004 Aug;4(8):630-40. doi: 10.1038/nri1417.
10
Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
Int Immunol. 2005 May;17(5):637-48. doi: 10.1093/intimm/dxh245. Epub 2005 Apr 11.
引用本文的文献
1
Phylogenetic Characterization of HIV-1 Sub-Subtype A1 in Karachi, Pakistan.
Viruses. 2022 Oct 20;14(10):2307. doi: 10.3390/v14102307.
2
Topological perspective on HIV escape.
Science. 2019 May 3;364(6439):438-439. doi: 10.1126/science.aax4989.
3
HIV-1 Vaccine Trials: Evolving Concepts and Designs.
Open AIDS J. 2012;6:274-88. doi: 10.2174/1874613601206010274. Epub 2012 Nov 30.
4
Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.
Antimicrob Agents Chemother. 2012 Jan;56(1):479-86. doi: 10.1128/AAC.05491-11. Epub 2011 Nov 7.
5
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.
J Virol. 2009 Sep;83(17):8300-14. doi: 10.1128/JVI.00114-09. Epub 2009 May 13.
6
Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs.
PLoS One. 2008 Jun 18;3(6):e2422. doi: 10.1371/journal.pone.0002422.
7
Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.
PLoS Pathog. 2008 Mar 21;4(3):e1000033. doi: 10.1371/journal.ppat.1000033.
8
A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames.
Retrovirology. 2006 Jan 6;3:1. doi: 10.1186/1742-4690-3-1.
9
Pre-exposure chemoprophylaxis for HIV: it is time.
Retrovirology. 2004 Jul 6;1:16. doi: 10.1186/1742-4690-1-16.
本文引用的文献
1
Reversion of CTL escape-variant immunodeficiency viruses in vivo.
Nat Med. 2004 Mar;10(3):275-81. doi: 10.1038/nm998. Epub 2004 Feb 15.
2
HIV evolution: CTL escape mutation and reversion after transmission.
Nat Med. 2004 Mar;10(3):282-9. doi: 10.1038/nm992. Epub 2004 Feb 8.
3
An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection.
J Biol Chem. 2003 Nov 7;278(45):44816-25. doi: 10.1074/jbc.M307546200. Epub 2003 Aug 27.
4
Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.
J Virol. 2003 Aug;77(16):9029-40. doi: 10.1128/jvi.77.16.9029-9040.2003.
5
HIV vaccines 1983-2003.
Nat Med. 2003 Jul;9(7):874-80. doi: 10.1038/nm0703-874.
6
The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.
J Virol. 2003 Jun;77(12):6889-98. doi: 10.1128/jvi.77.12.6889-6898.2003.
7
Development of prophylactic AIDS vaccines: the current state of affairs.
Curr Opin Mol Ther. 2003 Feb;5(1):25-32.
8
Viral evolution and challenges in the development of HIV vaccines.
Vaccine. 2002 Dec 19;20 Suppl 4:A66-8. doi: 10.1016/s0264-410x(02)00390-0.
9
HIV: current opinion in escapology.
Curr Opin Microbiol. 2002 Aug;5(4):408-13. doi: 10.1016/s1369-5274(02)00339-9.
10
Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.
J Virol. 2002 Aug;76(16):8276-84. doi: 10.1128/jvi.76.16.8276-8284.2002.
Zotero 插件